Windsor Private Capital LP
CIK: 0002034160
Associated companies
Transaction History
| AIFF | ▼ Sell | Open Market | 78,031 | $162K | 10/22/2025 | View on chart |
| AIFF | ▼ Sell | Open Market | 19,222 | $46K | 10/21/2025 | View on chart |
| AIFF | ▼ Sell | Open Market | 33,500 | $82K | 10/20/2025 | View on chart |
| AIFF | ▼ Sell | Open Market | 45,036 | $115K | 10/17/2025 | View on chart |
| AIFF | ▼ Sell | Open Market | 40,139 | $106K | 10/16/2025 | View on chart |
| AIFF | ▼ Sell | Open Market | 17,500 | $48K | 10/15/2025 | View on chart |
| AIFF | ▼ Sell | Open Market | 29,500 | $81K | 10/14/2025 | View on chart |
| AIFF | ▼ Sell | Open Market | 32,136 | $85K | 10/13/2025 | View on chart |
| AIFF | ▼ Sell | Open Market | 74,810 | $202K | 10/10/2025 | View on chart |
| AIFF | ▼ Sell | Open Market | 30,126 | $89K | 10/9/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Firefly Neuroscience Partners with Neurosigma for Pediatric ADHD Care
Firefly Neuroscience announced a partnership with Neurosigma to expand non-drug treatment options for pediatric ADHD. This move aims to broaden the company's clinical reach in the neurotechnology sector. The stock is currently trading within its 52-week range, with recent volume reflecting interest in this strategic development.
Firefly Neuroscience Partners with Neurosigma for Pediatric ADHD Care. Firefly Neuroscience announced a partnership with Neurosigma to expand non-drug treatment options for pediatric ADHD. This move aims to broaden the company's clinical reach in the neurotechnology sector. The stock is currently trading within its 52-week range, with recent volume reflecting interest in this strategic development.